Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Towns proposes FDA drug recall bill

This article was originally published in The Tan Sheet

Executive Summary

The House Oversight and Government Reform Committee chairman introduces legislation to authorize FDA to mandate recalls of adulterated, misbranded or potentially unsafe drugs. Rep. Edolphus Towns offered 1H.R. 5740 July 15; the bill awaits action by the Energy and Commerce Committee. "Too often, the FDA has been in the position of having to persuade companies to recall suspect products," the New York Democrat said, adding H.R. 5740 would give the agency "the full authority to pull contaminated medication from the market when necessary." Towns' bill responds directly to Johnson & Johnson's extensive recalls of OTC children's products and his committee's investigation of the firm's manufacturing problems and FDA's response to them (2"The Tan Sheet" May 31, 2010). FDA currently has mandatory recall authority for medical devices, but not for drugs or dietary supplements

You may also be interested in...

Senate Bill Expands FDA's OTC Manufacturing Oversight

Legislation introduced in the Senate to give FDA mandatory recall authority for all drugs would bar the agency from considering a drug's prescription status when assessing risk to prioritize inspections

FDA To Toughen OTC Oversight, Seek New Authority In Wake Of J&J Recalls

FDA will monitor more closely OTC manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare

England’s Innovative Medicines Fund To Put Spotlight On Rare Disease Treatments

While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts